Pheast Therapeutics

Pheast Therapeutics, founded with a mission to innovate cancer immunotherapy, focuses on developing novel checkpoint therapies that harness the innate immune system to combat cancer. The company is dedicated to creating treatments that target specific immune checkpoints, such as their lead candidate PHST001, an anti-CD24 macrophage checkpoint inhibitor. Pheast aims to revolutionize the cancer treatment landscape by enhancing the body's natural ability to fight tumors, targeting a market that includes patients with various forms of cancer.

Notable achievements for Pheast Therapeutics include raising $76 million in Series A funding and being featured as one of Nature Biotechnology’s top academic spinouts. The company has also unveiled promising preclinical data for PHST001, highlighting its potential in cancer immunotherapy. With significant backing from investors and recognition from industry leaders, Pheast Therapeutics is poised to make a substantial impact on the future of cancer treatment by advancing innovative therapies that leverage the immune system's power.